Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined carvedilol and saroglitazar therapy for hepatic fibrosis in MASLD
TCTR20260405010Recruiting
- Sponsor
- INDRAJIT SURESH
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of carvedilol and saroglitazar in metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatic fibrosis, sponsored by INDRAJIT SURESH. Started Mar 2026; status: recruiting.
02
Drugs
carvedilolsaroglitazar
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)hepatic fibrosis
Beyond the preview
Go deeper on TCTR20260405010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260405010.